reports
Castle Creek Pharmaceutical Holdings to Acquire Fibrocell
Castle Creek Pharmaceutical Holdings to Acquire Fibrocell - Total consideration of $63.3 million, including repayment of debt and other financial instruments - - Acquisition expected to close in the fourth quarter of 2019 - - Further strengthens Castle Creek Pharmaceuticals as a leader in dermatology - EXTON, Pa., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced it has reached an agreement to be acquired by Castl...
Fibrocell Reports Second Quarter 2019 Financial Results and Recent Ope...
Fibrocell Reports Second Quarter 2019 Financial Results and Recent Operational Highlights - Company to Host Conference Call and Webcast on Thursday, August 15 at 8:30 a.m. EDT - EXTON, Pa., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for the second quarter ended June 30, 2019 and recent operational highlights. Fibrocell will also host a conference call and webcast on Thursday, August 15 at 8:30 am ED...
Fibrocell to Present at BIO International Convention 2019
Fibrocell to Present at BIO International Convention 2019 EXTON, Pa., May 30, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, President and Chief Executive Officer, will present at the BIO International Convention 2019 on Tuesday, June 4 at 1:00 pm EDT in Philadelphia, PA. Mr. Maslowski will discuss FCX-007, the Company’s gene therapy candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB)...
Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designat...
Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB EXTON, Pa., May 29, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to FCX-007, the Company’s gene therapy candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB)—a ...
Fibrocell Reports First Quarter 2019 Financial Results and Recent Oper...
Fibrocell Reports First Quarter 2019 Financial Results and Recent Operational Highlights Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT EXTON, Pa., May 15, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for the first quarter ended March 31, 2019 and recent operational highlights. Fibrocell will host a conference call and webcast at 8:30 am EDT today. “We achieved important milestones during t...
Fibrocell to Host Conference Call and Webcast on Wednesday, May 15, 20...
Fibrocell to Host Conference Call and Webcast on Wednesday, May 15, 2019 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights EXTON, Pa., May 09, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will report financial results for the first quarter ended March 31, 2019 and recent operational highlights on Wednesday, May 15, 2019 before the open of the U.S. financial markets. Fibrocell will also host a conference call and we...
Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to...
Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy - Fibrocell to receive up to $135 million, including up to $30 million in upfront, near-term and development payments and a 30% gross profit share - - Fibrocell retains rights to the eligible Rare Pediatric Disease Priority Review Voucher - - Phase 3 clinical trial (DEFI-RDEB) initiation expected in second quarter of 2019 - - Fibrocell to host conference call at 8:30 AM EDT Today - EXTON, Pa., April 15, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), ...
Fibrocell Announces Board Member Christine St.Clare Honored by Nationa...
Fibrocell Announces Board Member Christine St.Clare Honored by National Association of Corporate Directors - Annual NACD Directorship 100 List Recognizes the Most Influential Corporate Governance Experts - EXTON, Pa., April 03, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced Christine St.Clare, a member of the Company’s Board of Directors and Audit Committee Chair, has been recognized by the National Association of Corporate Director...
Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeti...
Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007 - Phase 3 clinical trial, named DEFI-RDEB, is expected to commence in the second quarter of 2019 - - Additional data from Phase 1/2 clinical trial demonstrates FCX-007 continues to be well tolerated with continued positive trends in wound healing - - Company reports full year 2018 financial results - - Conference call & webcast scheduled at 8:30 a.m. EDT today - EXTON, Pa., March 27, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene the...
Fibrocell to Present at 21st Annual BIO CEO & Investor Conference
Fibrocell to Present at 21st Annual BIO CEO & Investor Conference EXTON, Pa., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, President and Chief Executive Officer, will present at the 21st Annual BIO CEO & Investor Conference on Monday, February 11 at 9:45 am EST in New York City. Mr. Maslowski will discuss the Company’s gene therapy candidates for rare diseases: FCX-007 for the treatment of recessive dy...
Fibrocell to Present at Phacilitate Leaders World 2019
Fibrocell to Present at Phacilitate Leaders World 2019 EXTON, Pa., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, President and Chief Executive Officer, will present at Phacilitate Leaders World 2019 on Wednesday, January 23 at 2:05 pm EST in Miami, Florida. Mr. Maslowski will discuss FCX-007, the company’s gene therapy candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a d...
Fibrocell Receives $900,000 Investment from EB Research Partnership an...
Fibrocell Receives $900,000 Investment from EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation Funding to Help Further Clinical Development of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa EXTON, Pa., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that EB Research Partnership, Inc. (EBRP) and Epidermolysis Bullosa Medical Research Foundation (EBMRF) have invest...
Fibrocell Reports Third Quarter 2018 Financial Results and Recent High...
Fibrocell Reports Third Quarter 2018 Financial Results and Recent Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.m. EST – - Announces patient enrollment completed in Phase 2 of Phase 1/2 clinical trial for FCX-007 for recessive dystrophic epidermolysis bullosa - EXTON, Pa., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for the third quarter ended September 30, 2018 and recent ope...
Fibrocell to Host Conference Call and Webcast on Tuesday, November 13,...
Fibrocell to Host Conference Call and Webcast on Tuesday, November 13, 2018 to Discuss Third Quarter 2018 Financial Results and Recent Highlights EXTON, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will report financial results for the third quarter ended September 30, 2018 and recent operational highlights on Tuesday, November 13, 2018 before the open of the U.S. financial markets. Fibrocell will also host a conference call and web...
Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design ...
Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007 Company Plans to Submit Phase 3 Protocol to FDA in Fourth Quarter of 2018 and Commence Trial in First Half of 2019 EXTON, Pa., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced completion of a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss the design of a Phase 3 clinical trial protocol of FCX-007, the Company’s g...
Fibrocell to Present at Upcoming Industry and Investor Conferences
Fibrocell to Present at Upcoming Industry and Investor Conferences EXTON, Pa., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, President and Chief Executive Officer, will present at these industry and investor conferences in October 2018: Cell & Gene Meeting on the Mesa on Wednesday, October 3rd at 3:00 p.m. PDT in La Jolla, CA Chardan 2nd Annual Genetic Medicines Conference on Tuesday, October 9th at...
Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatm...
Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa EXTON, Pa., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U.S. Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) has awarded a $1.4 million clinical trial research grant for Fibrocell’s continued clinical development of FCX-007, the Company’s gene therapy candidate...
Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatmen...
Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma EXTON, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to FCX-013, the Company’s clinical stage candidate for the treatment of moderate to severe localized scleroderma—a chronic, debilitating genetic skin disorder with no FD...
Fibrocell to Present at 20th Annual Rodman & Renshaw Global Investment...
Fibrocell to Present at 20th Annual Rodman & Renshaw Global Investment Conference EXTON, Pa., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, President and Chief Executive Officer, will present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H. C. Wainwright & Co., LLC. Mr. Maslowski’s presentation is scheduled for Wednesday, September 5 at 2:35 p.m. EDT in New York City. ...
Fibrocell Reports Second Quarter 2018 Financial Results and Recent Hig...
Fibrocell Reports Second Quarter 2018 Financial Results and Recent Highlights Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT EXTON, Pa., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for the second quarter ended June 30, 2018 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m. EDT. “During the second quarter of 2018, we attained ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.